Recombinant Human PAFAH/PLA2G7 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3756
Validation Data Gallery
Product Information
Purity | >90 %, SDS-PAGE |
Endotoxin | <0.1 EU/μg protein, LAL method |
Activity |
Not tested |
Expression | HEK293-derived Human PAFAH protein Phe22-Asn441 (Accession# Q13093) with a rabbit IgG Fc tag at the C-terminus. |
GeneID | 7941 |
Accession | Q13093 |
PredictedSize | 74.1 kDa |
SDS-PAGE | 70-90 kDa, reducing (R) conditions |
Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
PAFAH(platelet-activating factor acetylhydrolase, plasma) is also named as PLA2G7(phospholipase A2, group VII), Lp-PLA2 (Lipoprotein-associated phospholipase A2), LDL-PLA2, LDL-PLA and belongs to the AB hydrolase superfamily and lipase family. It is an enzyme that catalyzes the hydrolysis of acetyl ester at the sn-2 position of PAF. The family of PAF-Ahs consists of two intracellular isoforms (Ib and II), and one secreted isoform (plasma). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PAFAD), susceptibility to asthma (ASTHMA), and susceptibility to atopic hypersensitivity (ATOPY).
References:
1. Marie E Bechler. et al. (2010). J Cell Biol. 190(1):45-53. 2. Marie E Bechler. et al. (2013).Biochim Biophys Acta. 1831(3):595-601. 3. Ken Karasawa. et al. (2003). Prog Lipid Res. 42(2):93-114